Gonadotropin releasing hormone agonist for luteal phase support The origin of the concept current experience mechanism of action and future perspectives

Thursday, April 21, 2016

Authors:
Jan Tesarik, M.D., Ph.D., Raquel Mendoza-Tesarik, Ph.D., Nicolas Mendoza, M.D.…

Read More

Intranasal gonadotropin releasing hormone agonist GnRHa for luteal phase support following GnRHa triggering a novel approach to avoid ovarian hyperstimulation syndrome in high responders

Tuesday, April 5, 2016

Authors:
Itai Bar-Hava, M.D., Yossi Mizrachi, M.D., Daphne Karfunkel-Doron, M.Sc., Yeela Omer, B.A., Liron Sheena, M.D., Nurit Carmon, Bs.C.D.R., Gila Ben-David, M.D.…

Read More

Risk factors for a suboptimal response to gonadotropin releasing hormone agonist trigger during in vitro fertilization cycles

Tuesday, September 1, 2015
Risk factors for suboptimal response to gonadotropin-releasing hormone agonist-agonist trigger include low luteinizing hormone (LH) and follicle stimulating hormone on in vitro fertilization cycle start day, low LH on trigger day, history of irregular menses, and long-term oral contraceptive use.

Read More

Gonadotropin releasing hormone agonists for the preservation of ovarian function among women with breast cancer who did not use tamoxifen after chemotherapy A systematic review and meta analysis

Tuesday, June 3, 2014
Resumption of menses 1 year or more after treatment is similar among women with breast cancer who receive a gonadotropin-releasing hormone agonist with chemotherapy or chemotherapy alone.

Read More

Maternal and neonatal outcomes after gonadotropin releasing hormone agonist trigger for final oocyte maturation in patients undergoing in vitro fertilization

Tuesday, May 20, 2014
Gonadotropin-releasing hormone agonist trigger does not affect obstetrical or neonatal outcomes in antagonist cycles.

Read More

Preventing ovarian hyperstimulation with gonadotropin releasing hormone agonist trigger Is anything perfect

Monday, March 31, 2014
Reflections on "Severe ovarian hyperstimulation syndrome after gonadotropin-releasing hormone (GnRH) agonist trigger and “freeze-all” approach in GnRH antagonist protocol" by Fatemi et al.

Read More

Reference range for the antimullerian hormone Generation II assay A population study of 10984 women with comparison to the established Diagnostics Systems Laboratory nomogram

Friday, January 31, 2014
Antimüllerian hormone (AMH) exhibits an age-related decline, but the population distribution suggests that the current AMH Generation II assay standardization is not as reported by the manufacturer.

Read More

Measurement of antimüllerian hormone not as straightforward as it seems

Friday, January 31, 2014
Reflections on "Reference range for the antimüllerian hormone Generation II assay: a population study of 10,984 women, with comparison to the established Diagnostics Systems Laboratory nomogram" by Nelson et al.

Read More

Impact of final oocyte maturation using gonadotropin releasing hormone agonist triggering and different luteal support protocols on endometrial gene expression

Tuesday, December 31, 2013
Genes related to endometrial receptivity were analyzed on 25 endometrial samples after GnRH-a triggering and different luteal support protocols; adding LH/hCG activity more closely resembles the expression after hCG triggering.

Read More

Dual trigger with combination of gonadotropin releasing hormone agonist and human chorionic gondadotropin significantly improves live birth rate for normal responders in GnRH antagonist cycles

Thursday, October 31, 2013
Dual trigger with gonadotropin-releasing hormone (GnRH) agonist and human chorionic gonadotropin improves implantation, clinical pregnancy, and live-birth rates for normal responders in GnRH-antagonist IVF-ICSI cycles.

Read More

Cost effectiveness comparison between pituitary down regulation with a gonadotropin releasing hormone agonist short regimen on alternate days and an antagonist protocol for assisted fertilization treatments

Tuesday, April 30, 2013
Although the controlled ovarian stimulation protocol with short GnRH agonist in alternate days may lower the cost of an individual IVF cycle, it requires more cycles to achieve pregnancy.

Read More

Aromatase Inhibitors for the Treatment of Endometriosis

Thursday, November 29, 2012
A review is presented of the role of aromatase in the pathogenesis of endometriosis, discuss the pharmacology of aromatase inhibitors, and examine clinical applications of aromatase inhibitors for endometriosis treatment.

Read More

Ovarian stimulation and fertility preservation using aromatase inhibitors in women with breast cancer

Thursday, November 29, 2012
Studies suggest that in the short term, an aromatase inhibitor plus gonadotropin protocol is effective for safely inducing controlled ovarian hyperstimulation in women with breast cancer for fertility preservation.

Read More

Serum levels of antimüllerian hormone in early maturing girls before, during, and after suppression with GnRH agonist

Thursday, November 1, 2012
Circulating AMH declined significantly after gonadal suppression with long-acting GnRH agonist, and AMH recovered to pretreatment levels after discontinuation of GnRH agonist. This is an indication of partial gonadotropin-dependence of AMH.

Read More

Gonadotropin Releasing Hormone agonist may minimize premature ovarian failure in young women undergoing autologous stem cell transplantation

Thursday, November 1, 2012
Gonadotropin-releasing hormone agonist cotreatment in conjunction with conditioning chemotherapy before stem cell transplantation may significantly decrease gonadotoxicity and premature ovarian failure in lymphoma but not in leukemia patients.

Read More

Premature progesterone rise negatively correlated with live birth rate in IVF cycles with GnRH agonist: an analysis of 2,566 cycles

Tuesday, June 12, 2012
This retrospective analysis showed that premature progesterone rise (PPR) impaired in vitro fertilization outcomes in fresh embryo transfer, whereas no negative impact on frozen embryo transfer was observed, implying deleterious effects of PPR on endometrial receptivity.

Read More

Subtle progesterone rise on the day of hCG administration is associated with lower live birth rates in women undergoing assisted reproductive technology: a retrospective study with 2,555 fresh embryo transfers

Friday, June 8, 2012
In this retrospective, observational, cohort study with 2,555 women, a rise of serum P levels on the day of hCG administration was associated with a reduced live birth rate after day-5 fresh ET.

Read More

Dual trigger of oocyte maturation with gonadotropin-releasing hormone agonist and low-dose human chorionic gonadotropin to optimize live birth rates in high responders

Wednesday, May 30, 2012
Dual trigger with GnRH agonist and low-dose hCG in high responders with peak E2 levels <4,000 pg/mL improves live birth rates.

Read More

Translate »